Introducing the VKORC1 -1639G>A RealFast Assay – the fast and accurate real-time PCR test for detecting the most relevant tag-SNP associated with interpatient variability in dose requirements for oral anticoagulants, like warfarin, phenprocoumon, or acenocoumarol.

The VKORC1 gene plays a crucial role in the vitamin K pathway and is a target of vitamin K antagonists, which are widely prescribed as oral anticoagulants for the prevention and treatment of thromboembolic disorders. However, their narrow therapeutic range and wide variation in drug response complicate treatment, particularly at the beginning, and increase the risk of bleeding or thromboembolism.

The VKORC1 -1639G>A RealFastTM Assay identifies the three possible VKORC1-1639G>A genotypes – GG (normal dose), GA (intermediate dose), or AA (low dose) – in a human DNA extract. Homozygous carriers of the A allele require a lower dose of oral anticoagulants than heterozygous or homozygous carriers of the G allele. Empirical dosing may result in frequent dose changes as the international normalized ratio (INR) fluctuates, but personalized dosing guided by genetic testing improves therapeutic outcomes.

Trust in Viennalab’s expertise and experience in molecular diagnostics to provide you with reliable and easy-to-use results for your laboratory workflow. Improve patient safety and reduce the risk of bleeding or thromboembolism associated with oral anticoagulant treatment – add the VKORC1 -1639G>A RealFastTM Assay to your laboratory today.